Avanir to Present at the Jefferies 2010 Global Life Sciences Conference
ALISO VIEJO, Calif., June 1, 2010 - AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that the Company will present at the Jefferies & Company, Inc. 2010 Global Life Sciences Conference on Tuesday, June 8th at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in New York. The Jefferies 2010 Global Life Sciences Conference provides participating companies with the opportunity to present to institutional and private equity investors and leading healthcare executives.
A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the Jefferies Global Life Sciences Conference will be available on the Company's website for 30 days.
AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia™, has completed a confirmatory Phase III trial in the treatment of pseudobulbar affect (PBA). AVANIR has filed an application for regulatory approval in the PBA indication and the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 30, 2010. The Company's first commercialized product, Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. AVANIR has also completed a Phase III trial of Zenvia in patients with diabetic peripheral neuropathic (DPN) pain. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.
Eric Benevich/Brenna Mullen
Jun 01, 2010